Association of apolipoprotein B/apolipoprotein A1 ratio and cardiovascular events in rheumatoid arthritis: results of the CARMA study.

CONCLUSIONS: No association between ApoB/apoA1 ratio and CVE was found at the baseline visit of patients with RA from the CARMA study. PMID: 31694752 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research

Related Links:

Condition:   Arthritis, Rheumatoid Interventions:   Drug: Simvastatin 20 mg;   Drug: Methotrexate 10 mg Sponsor:   King Edward Medical University Completed
Source: - Category: Research Source Type: clinical trials
Authors: El Menshawe SF, Nafady MM, Aboud HM, Kharshoum RM, Elkelawy AMMH, Hamad DS Abstract The current study aimed to encapsulate fluvastatin sodium (FVS), a member of the statins family possessing pleiotropic effects in rheumatoid arthritis (RA), into spanlastic nanovesicles (SNVs) for transdermal delivery. This novel delivery could surmount FVS associated oral encumbrances such as apparent first-pass effect, poor bioavailability and short elimination half-life, hence, accomplishing platform for management of RA. To consummate this objective, FVS-loaded SNVs were elaborated by thin film hydration method, utilizi...
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
AbstractObjectivesTo explore incidence and progression of coronary atherosclerosis and identify determinants thereof in patients with rheumatoid arthritis. We specifically evaluated the impact of inflammation, cardiac risk factors, duration of medication exposure and their interactions on coronary plaque progression.MethodsOne hundred ‐one participants with a baseline coronary computed tomography angiography underwent follow‐up assessment in 83±3.6 months. Plaque burden was reported as segment involvement score (SIS) describing the number of coronary segments with plaque and segment stenosis score (SSS) characte...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: FULL LENGTH Source Type: research
ObjectiveRheumatoid arthritis (RA) is associated with increased cardiovascular event (CVE) risk. The impact of statins in RA is not established. We assessed whether atorvastatin is superior to placebo for the primary prevention of CVEs in RA patients.MethodsA randomized, double ‐blind, placebo‐controlled trial was designed to detect a 32% CVE risk reduction based on an estimated 1.6% per annum event rate with 80% power atP50 years or with a disease duration of>10 years who did not have clinical atherosclerosis, diabetes, or myopathy received atorvastatin 40 mg daily or matching placebo. The primary end point was a c...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Original Article Source Type: research
Purpose of review Uncertainty persists about the contribution of lipids to the increased risk of cardiovascular disease (CVD) among rheumatoid arthritis and other inflammatory joint disease (IJD) patients. In reviewing recent research, we consider potential insights gained by quantifying lipoprotein particles directly, rather than by their lipid content. Recent findings Although inflammation often decreases LDL cholesterol (LDL-C), and anti-inflammatory medications often increase LDL-C, both inflammation and anti-inflammatory medications can increase atherogenic Apolipoprotein B (ApoB)-containing lipoprotein particles...
Source: Current Opinion in Lipidology - Category: Lipidology Tags: HYPERLIPIDAEMIA AND CARDIOVASCULAR DISEASE: Edited by Paul N. Durrington Source Type: research
More News: Arthritis | Cardiology | Cardiovascular | Cholesterol | Heart | Rheumatoid Arthritis | Rheumatology | Spain Health | Statin Therapy | Statistics | Study